KIMS Pharmaceutical announced on the 20th that it has signed a contract with Japanese pharmaceutical company Mitsubishi Tanabe Pharma on the 17th to license Lipothasone.

Through this contract, KIMS Pharmaceutical will officially release the product in August. According to KIMS Pharmaceutical, Lipothasone is the only Dexamethasone in Korea that uses Mitsubishi Tanabe Pharma's Lipid Nano Particle (LNP) technology.

Steroids are excellent enough to be called panacea, but it is a drug that is reluctant to be prescribed due to serious side effects.

Lipothasone is known to be a strong and safe anti-inflammatory treatment as well as targeted treatment of inflammatory areas by redu